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Background. Invasive meningococcal disease (IMD), sepsis and/or meningitis continues to be a public health problem, with 
mortality rates ranging from 5% to 16%. The aim of our study was to further knowledge about IMD with a large series of cases occur-
ring over a long period of time, in a cohort with a high percentage of adult patients.
Methods. Observational cohort study of patients with IMD between 1977 hand 2013 at our hospital, comparing patients with 
only sepsis and those with meningitis and several degrees of sepsis. The impact of dexamethasone and prophylactic phenytoin was 
determined, and an analysis of cutaneous and neurological sequelae was performed.
Results. A total of 527 episodes of IMD were recorded, comprising 57 cases of sepsis (11%) and 470 of meningitis with or 
without sepsis (89%). The number of episodes of IMD decreased from 352 of 527 (67%) in the first to 20 of 527 (4%) in the last 
quarter (P < .001). Thirty-three patients died (6%): 8 with sepsis (14%) and 25 with meningitis (5%) (P = .02). Cutaneous and neu-
rological sequelae were present in 3% and 5% of survivors of sepsis and meningitis, respectively. The use of dexamethasone was safe 
and resulted in less arthritis, and patients given prophylactic phenytoin avoided seizures.
Conclusions. The frequency of IMD has decreased sharply since 1977. Patients with sepsis only have the highest mortality and 
complication rates, dexamethasone use is safe and can prevent some arthritis episodes, and prophylactic phenytoin might be useful 
in a selected population. A rapid response and antibiotic therapy may help improve the prognosis.
Keywords. Invasive meningococcal disease; sepsis; sequelae
Invasive meningococcal disease (IMD), involving sepsis and/or 
meningitis, continues to be a public health problem, with an 
overall mortality rate ranging from 5% to 16%. Meningococcal 
disease was first described as an outbreak in Geneva, 
Switzerland, in 1805 [1]. The etiological agent was later iden-
tified as Neisseria meningitidis, and in the first half of the 20th 
century there were major advances in therapy and, therefore in 
prognosis, with the discovery and implementation of sulfon-
amides and penicillin therapy [2]. 
Effective vaccines for some of the serogroups were also intro-
duced in the second half of the 20th century [3–5]. Recently, 
much attention has been focused on serogroup B prevention 
after the licensure of novel, protein-based, multicomponent vac-
cines in Europe [6]. However, IMD remains prevalent through-
out the world and is a serious health problem. Characteristics 
of the disease, such as the rapidity with which it may cause 
death in previously healthy persons, the potentially large size of 
outbreaks due to person-to-person spread through the air, and 
hyperendemic situations, make it a dreaded disease and often 
the cause of tremendous public concern. Several problems and 
questions remain unresolved: the existence of the “meningitis 
belt” in sub-Saharan Africa, the treatment of fulminant menin-
gococemia, the widespread availability of effective vaccines, 
and the best antibiotic therapy and its duration in cases with 
resistance to penicillin or changes in prevalent serogroups as 
vaccines are administered.
The epidemiology of IMD is dynamic, and there are continu-
ous changes in its incidence rate and predominant serogroups. 
In the United States, the annual incidence rate varies in multi-
year cyclical waves, from 0.5 to 2.0 cases per 100 000 persons. In 
sub-Saharan Africa the rate ranged from 10–25/100 000 before 
the successful use of MenAfriVac and can exceed 500/100 000 
during epidemics [7–12]. 
Endemic disease may be due to one of several serogroups, but 
85%–90% of cases are due to serogroups A, B, or C. Serogroups 
B and C are more common in Europe and the Americas, and 
serogroups A and C predominate in Africa and Asia [8, 9, 13, 
14]. There has been a remarkable increase in invasive capsular 
group W disease causing severe disease in England and Wales in 
recent years [15], as also observed in other European countries 
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and in Chile, Argentina, and South Africa [16]. Serogroup 
Y was most common in Japan [16]. Recently, a higher inci-
dence and several clusters of meningococcal disease have been 
described among men who have sex with men [17]. In Spain, 
endemic cases are mostly due to serogroup B. The last epidemic 
outbreak was in 1996–1997 and was due to serogroup C; as a 
consequence, meningococcal C conjugate vaccine was intro-
duced to the childhood vaccination schedule in 2000 [18]. In 
Catalonia, the rate in 2016 was 0.8/100 000 but had been as high 
as 18.6/100 000 in 1979 [19].
Besides vaccination, the key means of prevention, early 
recognition and aggressive treatment are the only effective 
measures against this invasive disease. The immediate adminis-
tration of antibiotic therapy and the recognition and treatment 
of patients who may have complications of IMD, such as shock, 
raised intracranial pressure, or both, are required in order to 
prevent death. As meningococcal disease incidence fluctuates, 
knowledge about the disease and the responsiveness necessary 
to act effectively in a new case may be scarce in new genera-
tions of health personnel. The objective of the present study was 
to increase knowledge about IMD with a large series of cases 
occurring over a long period of time, in a cohort with a high 
percentage of adult patients.
METHODS
Patients
This was an observational cohort study of patients admitted 
to our hospital from 1977 to 2013 with IMD. The Hospital 
Universitari de Bellvitge is a large university hospital in 
Barcelona. Since 1977, all cases of bacterial meningitis or IMD 
have been routinely recorded in a 120-variable protocol. For 
the purpose of the present study, we selected all episodes of 
IMD, with or without meningitis. An episode was considered 
to have occurred when there were clinical findings of sepsis 
and/or meningitis and N.  meningitidis was isolated in blood, 
cerebrospinal fluid (CSF), pharyngeal swab, or joint fluid sam-
ples, or, in the absence of positive cultures, when gram-nega-
tive diplococci were detected from the CSF Gram stain or when 
patients presented with findings of acute bacterial meningitis 
or sepsis with characteristic skin lesions; both confirmed and 
possible cases are included. Patients with IMD were classified as 
those with sepsis (meningococcal disease without meningitis) 
and those with meningitis. Meningitis was diagnosed based on 
inflammatory CSF parameters, white blood cell (WBC) count 
≥5/μL, or positive CSF culture. Patients with meningitis mani-
fested varying symptoms and signs of the sepsis criteria, rang-
ing from none to septic shock.
From 1977 to 1994 our hospital admitted patients as young 
as 7  years. Since 1994, however, only patients aged ≥14  years 
have been admitted. From 1987, all patients with either sus-
pected pneumococcal meningitis or another type of bacterial 
meningitis with CSF pressure ≥30 cm H2O were systematically 
treated with dexamethasone (4 mg/6 h for 48 hours, initiated 
before or combined with the first antibiotic dose), and from 
2002 onward dexamethasone was widely used to treat bacterial 
meningitis, so several of our patients received this drug in the 
first 48 hours, always at the same dose (4 mg/6 h). Prophylaxis 
of seizures with phenytoin has also been carried out in patients 
with suspected pneumococcal meningitis or CSF pressure 
≥30 cm H2O since 1987, so several patients who had meningo-
coccal meningitis received this prophylaxis.
All patients were evaluated daily and underwent complete 
hematological counts and biochemical tests within 48 hours of 
admission, during hospitalization, and once more at the outpa-
tient clinic. All patients surviving IMD were monitored at the 
outpatient clinic and were followed up until resolution of all 
symptoms or their consideration as permanent sequelae 1 year 
after the initial infection.
Deaths during hospitalization were recorded. The mech-
anism of death was classified as early (first 48 hours) sepsis 
or neurological or late neurological or nonneurological (due 
to complications other than neurological problems). Lesions 
requiring plastic surgery repair or amputation were considered 
cutaneous sequelae. Neurological sequelae were considered at 
1 year. The duration of therapy was 7 days from 1977 to 1983 
and 4 days from 1984 to 2013 [20, 21].
The isolates were identified using conventional microbiolog-
ical methods [22]. Antibiotic susceptibility was systematically 
determined from 1993 (1 strain per patient). Minimum inhib-
itory concentrations (MICs) for penicillin, cefotaxime, chlo-
ramphenicol, rifampicin, and cotrimoxazole were determined 
by a microdilution method using commercial panels from 
the Sensititre system (TREK Diagnostic Systems), according 
to Clinical Laboratory Standards Institute recommendations. 
Clinical Laboratory Standards Institute criteria were used to de-
fine susceptibility or resistance [23].
Statistical Analysis
Simple linear regressions were conducted to assess changes in 
the frequency of IMD. Continuous variables were expressed 
as mean with standard deviation or median with interquar-
tile range (IQR). For descriptive analysis, categorical data were 
compared using χ2 or Fisher exact tests, and continuous data 
with t or Mann-Whitney tests.
RESULTS
Between 1977 and 2013, a total of 527 episodes of IMD were 
recorded at our hospital: 57 cases of sepsis (11%) and 470 of 
meningitis with or without sepsis (89%). The number of epi-
sodes of IMD decreased sharply during the study period, from 
352 of 527 (67%) recorded in the first quarter to 20 of 527 (4%) 
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−1.456 to −.960; P < .001), with 466 episodes (88%) occurring in 
the first half of the study period (Figure 1). For meningitis, the 
relative presence of each cause over time is presented in Table 
1. In the first 2 periods, meningococci represented the primary 
cause and in the third and fourth periods they were the second 
most prevalent. In the final period, Listeria monocytogenes was 
as prevalent as meningococci.
Clinical Characteristics
Demographic and clinical characteristics and details about 
the treatment and outcome of in patients with sepsis, patients 
with meningitis, and all patients combined are presented in 
Tables 2–4. Sixty-one percent of patients were women. A sig-
nificant underlying disease was present in 103 patients (20%); 
among these, diabetes mellitus was present in 49 (9%), 3 were 
receiving corticosteroids, and 1 was receiving chemotherapy. 
A total of 330 episodes (63%) occurred in the autumn-win-
ter period. There were differences in the time of consultation 
between sepsis-only and meningitis episodes, with patients 
with sepsis presenting earlier (<12 hours) or later (>48 hours) 
(Table 2).
Some ear, nose, and throat symptoms were common, with 
201 patients (38%) referring to a previous cold and 210 (41%) 
presenting with odynophagia. Fever was reported by 491 
patients (93%) though present in the emergency room in only 
330 (67%); 301 patients (69%) presented with chills, and shock 
was present in 68 (13%), 14 patients with sepsis only (25%) and 
54 with meningitis (12%) (P = .008). Skin lesions were present in 
443 patients (84%), and petechiae or ecchymosis in 416 (79%).
On admission, 217 patients (41%) were alert, 229 (44%) 
obtunded, 76 (14%) in a coma, and 2 (0.3%) in an arreactive 
coma; as expected, there were differences between patients with 
sepsis and those with meningitis: 2 patients with sepsis (4%) 
versus 76 (16%) with meningitis were in a coma or arreactive 
coma (P = .004), and 16 (28%) versus 291 (62%), respectively, 
were obtunded or in a coma (P <  .001). Cranial nerve palsies 
were present in 37 patients, and only in patients with meningi-

















































































































Figure 1. Number of cases of invasive meningococcal disease (IMD) per year. Abbreviation: CI, confidence interval. 




(n = 529) 1987–1996 (n = 223) 1997–2006 (n = 178) 2007–2013 (n = 128)
Neisseria meningitidis 321 (62) 95 (43) 34 (19) 20 (17)
Streptococcus pneumoniae 104 (20) 64 (29) 74 (42) 65 (51)
Listeria monocytogenes 10 (2) 12 (5) 22 (12) 22 (17)
Other streptococci 11 (2) 11 (5) 15 (8) 7 (5)
Haemophilus influenzae 5 (1) 5 (2) 9 (5) 7 (5)
Staphylococcus aureus 5 (1) 5 (2) 3 (2) 0
Escherichia coli 10 (2) 2 (1) 2 (1) 0
Othera 8 (1.5) 1 (0.4) 1 (1) 1 (0.7)
Unknown 55 (10) 28 (13) 18 (10) 6 (5)
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Table 2. Clinical Characteristics of Patients With Sepsis and or Meningitis
Characteristic
Patients, No. (%)a
P Value Total, No. (%) (N = 527)Sepsis (n = 57 [11%]) Meningitis (n = 470 [89%])
Age, median (IQR), y 20 (15–58) 19 (14–49) .46 19 (14–50)
Female sex 38 (67) 287 (61) .25 325 (61)
Serogroup     
 A 0 (0) 9 (4) 9 (3)
 B 18 (62) 193 (78)  211 (76)
 C 9 (31) 29 (12) .007 38 (14)
 Other 0 (0) 8 (3)  8 (3)
Underlying disease     
 Any disease 18 (32) 85 (18)  103 (20)
 Diabetes mellitus 5 (9) 44 (10) .56 49 (9)
 Alcoholism 3 (5) 14 (3) .28 17 (3)
 Chronic hepatic disease 2 (4) 7 (1) .25 9 (2)
 Solid neoplasm or hematological cancer 1 (2) 2 (0.64) .29 4 (0.7)
 Immunodeficiencyb 7 (14) 13 (3) <.001 20 (4)
 Epidemiological contact 14 (25) 54 (11) .008 68 (13)
 Previous antibiotic treatmentc 5 (9) 138 (29) <.001 143 (28)
Duration of disease     
 <12 h 18 (32) 84 (18) .01 102 (19)
 >48 h 16 (28) 61 (13) .002 77 (15)
Clinical characteristics     
 Odynophagia 23 (40) 187 (41) .51 210 (41)
 Fever 54 (95) 437 (93) .59 491 (93)
 Fever in emergency room 43 (78) 287 (65) .04 330 (67)
 Shock 14 (25) 54 (12) .008 68 (13)
 Headache 36 (63) 432 (93) <.001 468 (91)
 Nuchal stiffness 15 (27) 424 (90) <.001 439 (83)
 Nausea or vomiting 30 (55) 400 (88) <.001 430 (84)
Skin lesions 52 (91) 391 (83) .12 443 (84)
 Maculopapular rash 7 (12) 18 (4)  25 (5)
 Petechiae 33 (58) 305 (65)  338 (64)
 Ecchymosis 11 (19) 67 (14) .32 78 (15)
 Vesicular rash 1 (2) 1 (0.2)  2 (0.4)
Consciousness     
 Alert 41 (72) 176 (38)  217 (41)
 Obtunded 14 (25) 215 (46)  229 (44)
 Coma or arreactive coma 2 (4) 76 (16) .004 78 (15)
Cranial nerve palsy     
 Any 0 37 (8) .01 37 (7)
 VI 0 18 (4)  18 (3)
 VIII 0 10 (2)  10 (2)
 Other III/VII 0 6 (1.4)  6 (1.4)
 Several nerves 0 3 (0.6)  3 (0.6)
Hemiparesis 0 13 (3) .22 13 (2)
 Before therapy 0 7 (2)  7 (1)
 After starting therapy 0 6 (1.2)  6 (1.2)
Seizures 3 (5) 26 (6) .62 29 (6)
 Before therapy 2 (4) 14 (3)  16 (3)
 After starting therapy 1 (2) 12 (3) .59 13 ()
Abbreviations: IQR, interquartile range.
aData represent No. (%) of patients unless otherwise specified.
bImmunodeficiency also includes splenectomy, systemic lupus erythematosus, chemotherapy, and corticosteroid therapy. 
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therapy (between 24 hours and 1 week) (Table 2). Seizures were 
also present in patients with sepsis (5%) as febrile seizures.
Laboratory Data
Blood cultures were positive in 209 patients (40%), more fre-
quently in patients with sepsis only (37 patients [65%]) than 
in those with meningitis (172 [37%]) (P < .001); other cultures 
(skin and joint fluid) were positive in 19 patients (4%). Among 
patients with meningitis, the median (IQR) CSF pressure was 
30 (21–37) cm H2O; CSF was clear in 68 patients (16%), opales-
cent in 21 (5%), cloudy in 260 (59%), purulent in 85 (19%) and 
hemorrhagic in 4 (1%). The median CSF WBC count was 1970/
μL (IQR, 407–6200/μL), hypoglycorrhachia was present in 286 
patients (61%), proteinorrhachia >1 g/L in 116 patients (27%), 
and >5 g/L. Gram stain was positive in 276 patients (61%), and 
CSF culture in 312 (69%).
The serogroup was identified in 266 patients. The most fre-
quent serogroup was B, responsible for 211 episodes (76%), 
without significant variations during the study period. 
Serogroup C was the second more frequent, responsible for 38 
episodes (14%), 9 of 57 episodes of sepsis (31%) and 29 of 470 
episodes of meningitis (12%) (P = .007).
Data on susceptibility were available for 89 strains. For 
penicillin, MICs were ≤0.06  mg/L (susceptible) in 59 of 89 
strains (66%), 0.12–0.25 mg/L (intermediate) in 25 (28%), and 
≥0.5 mg/L (resistant) in 5 (6%). The highest MIC was 1 mg/L; 
for cotrimoxazole, MICs were ≤0.12/2.4 mg/L (susceptible) in 
38 of 89 strains (43%) and ≥0.5 mg/L (resistant) in 51 (57%). 
For cefotaxime, rifampicin, and chloramphenicol, all 89 strains 
(100%) were susceptible, with MICs ≤0.06, ≤0.5, and ≤2 
mg/L respectively.
Thrombocytopenia was more frequent (28%) in patients 
with sepsis than in those with meningitis (17%) (P = .04). The 
cause was established in 147 patients by positive blood and CSF 
culture, in 62 by blood culture only, in 165 only by CSF culture 
only, in 13 by positive pharyngeal swab samples, in 2 by other 
positive cultures, and in 12 by the presence in CSF of gram-neg-
ative diplococci with negative culture. In 126 patients, the cause 
was assumed based on the presence of petechiae or ecchymosis 
with other compatible clinical findings.
A computed tomographic scan was obtained at admission 
in 54 patients and was abnormal in 15, demonstrating brain 
edema in 4, hydrocephalus in 3, cerebritis in 1, brain infarction 
in 1, and previous disease in 6. In 20 patients, computed tomog-
raphy was performed during the hospital stay; 10 scans were 
considered normal, and the other 10 demonstrated hydroceph-
alus in 4 patients (not present at admission in 3), infarction in 3, 
cerebritis in 1, and previous disease in 2.
Therapy
Antibiotic Therapy
Antibiotic use is shown in Table 4. Penicillin and ceftriaxone 
were the most commonly used. There were no differences in 
therapy used between patients with sepsis and those with men-
ingitis. Short-duration therapy (4 days) was used in 263 patients 
(50%), considering patients with sepsis and those with menin-
gitis together.
Corticosteroid Therapy
After 1987, early dexamethasone (either before or combined with 
the first antibiotic dose) was used in 72 patients with meningitis 
(14%). A comparison between patients with meningitis admitted 
since 1987 who did or who did not receive early dexamethasone 
showed that patients receiving early dexamethasone were older 
(median [IQR] age, 38 [21–63] vs 21 [16–45] years; P < .001), 
more frequently had neck stiffness (98% vs 83%; P = .002), were 
more likely to be comatose at admission (28% vs 6%; P = .001), 
and more frequently had a CSF protein concentration >1 g (94% 
Table 3. Laboratory Test Results in Patients With Sepsis and/or Meningitis
Laboratory Result
Patients, No. (%)a
Sepsis (n = 57) Meningitis (n = 470) Total (n = 527)
Positive blood culture 37 (65) 172 (37)b 209 (40)
Positive pharyngeal swab sample 13/22 (59) 47/181 (46)b 60/203 (30)
Other positive cultures 8 11 19 (4)
Blood findings    
 Hemoglobin, median (IQR) 12.5 (12–13) 13 (12–14) 13 (12–14)
 WBC count >10 000/μL 36 (67) 409 (87)b 445 (86)
 WBC count <5000/μL 7 (13) 16 (3)b 23 (4)
 Thrombocytopenia 15 (28) 78 (17)b 93 (18)
 Prothrombin time >1.3 21 (41) 208 (44) 229 (43)
 Hyponatremia 8 (15) 106 (23) 114 (22)
 Hypokaliemia 15 (28) 166 (37) 181 (36)
 Hypernatremia 0 6 (1) 6 (1)
Abbreviations: IQR, interquartile range; WBC, white blood cell. 
aData represent No. (%) of patients unless otherwise specified.
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vs 65%; P  < .001) or >5  g (45% vs 19%; P  =  .001). They also 
presented with a lower frequency of fever (89% vs 99%; P = .01), 
fever in the emergency room (50% vs 70%; P = .01), shock (3% 
vs 16%; P = .009), and skin lesions (76% vs 89%; P = .04). Despite 
these differences, there were no differences in outcome, in either 
mortality or complication rates, except for fewer cases of catheter 
phlebitis (10% vs 25%; P = .02) and arthritis (3% vs 10%; P = .04) 
in patients receiving dexamethasone.
Antiseizure Propylaxis and Therapy
Antiseizure therapy was administered in 28 patients (5%) and 
antiseizure prophylaxis with phenytoin in 25 (5%), all of them 
Table 4. Therapy and Outcome in Patients with Sepsis and/or Meningitis
Therapy and Outcome
Patients, No. (%)a
Sepsis (n = 57 [11%]) Meningitis (n = 470 [89%]) Total (N = 527)
Therapy
 Short therapy (4 d) 33 (58) 230 (49) 263 (50)
 Penicillin 32 (56) 305 (65) 337 (64)
 Ampicillin 2 (4)b 5 (1)c 7 (1)
 Cefotaxime 2 (4) 10 (2) 12 (2)
 Ceftriaxone 19 (33) 136 (29) 155 (29)
 Chloramphenicol 1 (2) 9 (2) 10 (2)
 Other 1 3 4
 No therapy 0 2 (0.4) 2 (0.4)
 Antiseizure prophylaxis 0 25 (5) 25 (5)
 Heparin 6/53 (11) 33/465 (7) 39/518 (7.5)
 Mechanical ventilation 8 (14) 47 (10) 55 (10)
Outcome    
 Time to improvement in consciousness, median (IQR), d 1 (1–1) 1 (1–2) 1 (1–2)
 Time to fever <38°C, median (IQR), d 1 (1–2) 1 (1–3) 1 (1–3)
 Relapse of fever 6 (11) 74 (16) 80 (16)
 Arthritis 11 (19) 29 (6)d 40 (8)
 Pericarditis 1 (2) 9 (2) 10 (2)
 Heart failure 11 (19) 36 (7)d 47 (9)
 Renal failure 8 (14) 39 (8) 47 (9)
 Impaired liver function 2 (4) 35 (8) 37 (7)
 DIC 12 (21) 60 (13) 72 (14)
 Herpes 4 (7) 120 (26)d 124 (24)
 Catheter phlebitis 10 (18) 128 (27) 138 (27)
 Gastrointestinal symptomse 5 (9) 30 (6) 35 (7)
 Total hospital stay, median (IQR), d 8 (6–10) 9 (7–11) 9 (7–11)
 Relapse 0 0 0
Sequelae 1 (2) 37 (8) 38 (7)
 Cutaneous necrosis 1 (2) 16 (4) 17 (3)
 Epilepsy 0 1 (0.2) 1 (0.2)
 Cranial nerve palsy 0 2 (0.5) 2 (0.4)
 Hearing impairment 0 11 (2.5) 11 (2.4)
 Hemiparesis 0 4 (1) 4 (1)
 Hydrocephalus-shunt 0 1 (0.2) 1 (0.2)
 Other 0 2 (0.5) 2 (0.4)
Deaths (by mechanism)    
 Total 8 (14) 25 (5)d 33 (6)
 Early neurological 1 (2) 5 (1) 6 (1)
 Late neurological 0 2 (0.4) 2 (0.4)
 Early sepsis 6 (11) 12 (2.5) 18 (3)
 Late nonneurological 1 (2) 6 (1) 7 (1)
Abbreviations: DIC, disseminated intravascular coagulation; IQR, interquartile range.
aData represent No. (%) of patients unless otherwise specified.
bTwo of them + aminoglycosides. 
cOne of them + aminoglycosides. 
dSignificant at P < .05. 
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patients with meningitis. Patients receiving the prophylaxis 
were significantly older (median [IQR] age, 55 [29–66] vs 23 
[16–50] years; P < .001), more likely to show abuse of alcohol 
(13% vs 0%; P < .001), and more likely to have chronic hepatic 
disease (4% vs 0%; P = .02) or any predisposing disease (39% vs 
13%, P = .02) than those not receiving prophylaxis. No seizures 
were seen in patients with antiseizure prophylaxis. No differ-
ences in mortality or complication rates were seen among these 
patients.
Outcome
The median (IQR) duration to improved consciousness was 1 
(1–2) days, and the median duration to fever below 38ºC was 
1 (1–3) days, both significantly longer (P  =  .008 and .03, re-
spectively) among patients with meningitis. Relapse of fever 
occurred in 80 patients (16%). The most frequent complications 
(Table 4) were catheter phlebitis, herpes simplex labialis, dis-
seminated intravascular coagulation (DIC), heart failure, renal 
failure and arthritis, with arthritis and heart and renal failure 
more frequent and herpes less frequent among patients with 
sepsis. There were no relapses.
Deaths
Thirty-three patients died (6%), 8 with sepsis (14%) and 25 with 
meningitis (5%) (P = .02). The mechanism of death was mainly 
early sepsis (Table 4). Mortality rates decreased slightly over 
time, but no significantly. A comparison between dead and alive 
patients can be found in the Supplementary Data.
Cutaneous Sequelae
Among the survivors, cutaneous sequelae mainly due to necrosis 
were present in 17 patients (3%). In the univariate analysis of 
the survivors, statistically significant differences were found be-
tween patients with and those without cutaneous sequelae, in-
cluding the presence of shock (53% vs 12%; P < .001), presence 
of ecchymosis (94% vs 12%; P < .001) or petechiae/ecchymosis 
100% vs 78%; P  =  .02), positive blood cultures (82% vs 38%; 
P < .001), lower CSF WBC count (median [IQR], 44/μL [9–750/
μL] vs 1700/μL [266–6000/μL]; P = .002), less proteinorrhachia 
>1 g/L (43% vs 69%; P = .045), presence of thrombocytopenia 
(65% vs 17%; P < .001), prothrombin time >1.3 (94% vs 45%; 
P < .001), and presence of hypokalemia (69% vs 35%; P = .006). 
All these parameters pointed to more severe sepsis in 
patients with cutaneous sequelae. There were also differences 
in outcome, with patients with cutaneous sequelae requiring 
more mechanical ventilation (41% vs 10%; P = .001) and use of 
heparin (41% vs 6%; P < .001), and having a higher frequency 
of heart failure (47% vs 8%; P < .001), DIC (65% vs 12%; P < 
.001), or gastrointestinal complications (29% vs 6%, P = .003). 
Hospital stays were longer, with a median (IQR) of 12 (9–20) 
versus 9 (7–11) days (P = .004). Previous antibiotic use was sig-
nificantly more likely in patients without cutaneous sequelae 
(29% vs 0% in those with sequelae; P = .004), and patients with 
sequelae had a lower frequency of meningeal signs such as 
nuchal stiffness (65% vs 86%; P = .03) or nausea/vomiting (65% 
vs 85%; P = .04). 
Multivariate analysis showed ecchymosis as the only inde-
pendent risk factor related to cutaneous sequelae (odds ratio 
[OR], 54; 95% CI, 6.126–480.795). If we exclude ecchymosis, 
because it could be considered the same process as the depen-
dent variable, the presence of DIC (OR, 4.8; 95% CI, 1.291–
18.379) was the only independent risk factor, whereas young 
age (0.9; .940–.999) was protective.
Neurological Sequelae
Neurological sequelae were present only in 21 (5%) of the 
patients surviving meningitis (Table 4). In the univariate anal-
ysis of the survivors, variables related to neurological sequelae 
were age (median [IQR], 45 [12–60] vs 18 [14–44] years; 
P = .03), late consultation (>48 hours) (28% vs 12%; P = .02), 
presence of nausea/vomiting (100% vs 88%; P  =  .02), cranial 
nerve palsy (28% vs 6%; P < .001), hemiparesis (19% vs 2%; P < 
.001), seizures at any time (16% vs 4%; P =  .01), and seizures 
after antibiotic therapy (13% vs 1%; P = .001). The duration to 
improved consciousness was longer in patients with neurolog-
ical sequelae (median [IQR], 2 [1–3] vs 1 [1–2] days; P = .03), 
and hospital stays were also longer (median, 11 [10–19] vs 9 
[7–10] days; P < .001). 
In the multivariate analysis age (OR, 1.023; 95% CI, 1.004–
1.042) hemiparesis (2.9; 1.3–6.5) and cranial nerve affectation 
(1.6; 1.1–2.3) were independent risk factors. Because cranial 
nerve palsy and hemiparesis could be considered as cause and 
effect, an analysis excluding these 2 factors was performed, 
showing age (OR, 1.019; 95% CI, 1.002–1.036), presence of sei-
zures either at any time (3.8; 1.2–12.3) or after therapy (11.8; 
2.5–56.8), and late consultation (2.5; 1.0–6.2) as independent 
risk factors.
DISCUSSION
According to our results, cases of IMD decreased dramatically 
in our hospital throughout the study period. IMD has been no-
tifiable on clinical suspicion in Spain since 1981. The average 
annual incidence rate of meningococcal disease in Barcelona 
during the period 1987–1992 was 6.41/100  000 [24], and 
during the period 1982–2010 the incidence of meningococcal 
meningitis decreased by 66% (P < .001) [25]. Other global data 
for Spain [8] show an incidence of 3.52/100  000 in 1999 and 
0.88/100 000 in 2010, after the vaccine for group C was intro-
duced in 2001. 
Studies in European countries confirm a clear decrease [26, 
27]. In the Netherlands, annual incidence rates increased from 
0.5/100 000 in 1960 to 4.5 in 2001, and subsequently decreased 
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area and in Spain is in part due to vaccination against group 
C meningococci, with a decrease in group C meningococcal 
disease of 93% from 1987 to 2015 and 75% from 2001 to 2015 
in Catalonia, and in part due to herd immunization, as has 
been suggested in other European countries [29–31]. However, 
because group B was the most frequent etiological agent, the 
large decrease in overall IMD also seems to be due to stochastic 
changes in epidemiology of unknown causes, including possi-
bly changes in population behaviors. In fact the incidence of 
the different serogroups is constantly changing in the different 
countries, and these changes are not always is due to vaccine 
implementation or antibiotic use.
Our patients presented with meningitis in a high percentage 
of cases, with several degrees of accompanying sepsis. A high 
percentage of patients with meningitis presented with the clas-
sic signs and symptoms of meningitis, and the only features that 
suggested meningococcal meningitis were symptoms such as 
odynophagia, which were present in 40% of cases and are very 
rare in other etiologies, and, of course, skin lesions.
Treatment of IMD has not been a problem in terms of an-
tibiotic susceptibility in our patients, because the widespread 
use of third-generation cephalosporin, the antibiotic in use 
since the 1980s, is very safe. Another consideration in the 
treatment of meningitis is the use of dexamethasone. Before 
1987, dexamethasone was sometimes used as rescue therapy in 
patients whose condition worsened after the start of antibiotic 
therapy, but it seemed to be ineffective. After 1987, dexameth-
asone used as early adjunctive therapy before the antibiotic 
was a good treatment option for our patients. Patients who 
received dexamethasone, whose condition had been more se-
vere, showed no differences in outcome compared with those 
who did not receive dexamethasone. We could not demon-
strate a better evolution, and this was not a randomized trial, 
but some complications, such as arthritis, were less common 
among patients receiving early dexamethasone, maybe owing 
to the immunoallergic mechanisms of most arthritis-related 
episodes [32]. The same finding was reported in a Dutch study 
[33] comparing 2 cohorts of patients with meningococcal 
meningitis, the first from the era before use of dexametha-
sone and the second after implementation of dexamethasone 
therapy. The authors of that study found no differences in out-
come and no adverse effects but a significantly lower number 
of cases of arthritis in patients receiving dexamethasone.
Seizures are an important complication that could perhaps 
be avoided in selected cases by means of phenytoin prophy-
laxis. In our patients, phenytoin was used in certain particularly 
severe cases, and no patient receiving phenytoin experienced 
seizures. In a Brazilian series [34] the presence of seizures was 
independently related to mortality rate. Although ours was not 
a clinical trial, our data support the notion that selected patients 
(including elderly patients and those with previous brain 
infarction or lesions) may benefit from seizure prophylaxis in 
cases of meningococcal meningitis.
In conclusion, in this large series of IMD cases covering an 
extensive period of time, the frequency of IMD has decreased 
sharply. Sepsis-only cases had the highest mortality and com-
plication rates, dexamethasone was demonstrated to be safe 
and to prevent some arthritis episodes, and the use of prophy-
lactic phenytoin seemed useful in a selected population. A very 
rapid response and antibiotic therapy may help improve the 
prognosis.
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